Mary Syto

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer

Barbara J. Gitlitz, Eric Bernstein, Edgardo S. Santos et al. · Journal of Thoracic Oncology · 2014 · 35 citations · Full text

Medicine, Oncology, Pharmacology +12

Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

Jonathan Q. Tran, Peijin Zhang, Atalanta Ghosh et al. · Advances in Therapy · 2020 · 28 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

Biomarker‐based phase I dose‐escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer

Karen L. Reckamp, Barbara J. Gitlitz, Lin‐Chi Chen et al. · Cancer · 2010 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects

Jonathan Q. Tran, Peijin Zhang, Susan Walker et al. · Advances in Therapy · 2020 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies.

Gail J. Roboz, H. Jean Khoury, Jamile M. Shammo et al. · Journal of Clinical Oncology · 2012 · 10 citations

Medicine, Hematology, Pharmacology +17